Regeneron Pharmaceuticals will share in development of Tessera Therapeutics’ TSRA-196, a Phase 1-ready gene-editing therapy for alpha-1 antitrypsin deficiency (AATD). Other companies developing genetic medicines for this rare disease include Beam Therapeutics, Wave Life Sciences, Korro Bio, and AIRNA.
The post Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder appeared first on MedCity News.
Malicious Chrome Extension “ChatGPT Ad Blocker” Steals ChatGPT Conversations
As OpenAI introduces advertisements to its free tier, cybercriminals are seizing the opportunity to trick users with fake utility tools. Security researchers have discovered a
.webp?w=0&resize=0,0&ssl=1 "Hackers Use Phorpiex Botnet to Spread Ransomware, Sextortion, and Crypto-Clipping Malware")
